More than 50% of cancer patients carry TP53 mutations (28), and the most common type of mutation in TP53 is a missense mutation, which encodes a mutant P53 protein that not only inhibits the oncogenic effects of wild-type P53 but also exhibits new oncogenic functions, such as the promotion of cell proliferation, evasion of apoptosis, metabolic changes, and migration (27). Here, TP53 is linked to cancer.